From trials to triumph: Forecasting across the product lifecycle

Access our expert guide, ‘From trials to triumph: Forecasting across the product lifecycle’ a must-read for anyone involved in pharmaceutical product management and strategy. This informative playbook covers everything you need to know about how forecasting demands and considerations evolve at each stage of a product’s journey, including: Early-stage forecasting: Understand how to make informed […]

Share:

Download today








Access our expert guide, ‘From trials to triumph: Forecasting across the product lifecycle’ a must-read for anyone involved in pharmaceutical product management and strategy. This informative playbook covers everything you need to know about how forecasting demands and considerations evolve at each stage of a product’s journey, including:

  • Early-stage forecasting: Understand how to make informed decisions on whether to advance or halt clinical trials based on market size, preliminary trial results, and more.
  • Advanced clinical trials and beyond: Learn how forecasting shifts to assess market readiness, competition, and long-term commercial viability as your product progresses through Phase 2, Phase 3, and post-launch stages.
  • Real-world expert insights: Hear directly from our Director of Client Implementation on the critical decisions companies face and the key data points needed for accurate forecasting at every phase.
  • Tailored solutions for strategic success: Explore how customised forecasting models can support your organisation’s unique challenges and goals, from development to market maturity.

 

Download the playbook now and gain access to valuable insights that can shape the success of your asset development and commercialisation.

If you have any questions or would like to discuss how our forecasting solutions can support your specific needs, feel free to reach out. We’re here to help. 

Upcoming Webinar

World Preview 2026

Tuesday 16th June 2026 | 3pm BST

By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.

Related Content